FDMT
NASD 4D Molecular Therapeutics, Inc.$13.00 ↑ +0.00 (+0.00%) Trading Up from the previous close of $13.00, $0.47 below the day’s high of $13.47
- YTD change
- +73.33%
- vs 20-day SMA
- -7.58%
- vs 200-day SMA
- +23.46%
Price ranges
Price & Performance
+2.96 (+29.48%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 76.4% away from all-time highs of $55.11
- FDMT is up 73% since the beginning of the year
- FDMT is up 46% over the past 12 months
- FDMT is down 1% over the past 1 month
- 17% of all FDMT investors are betting against FDMT
FDMT reads neutral: price sits above one of the two key moving averages, the 12-month move is +34.4%.
- Previous minute
- +$0.26
- Last hour
- +$0.26
- Last 5 days
- -4.90%
- vs 8-day SMA
- -1.81%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
4DMT operates as a clinical-stage genetic medicines company focused on inventing and developing genetic medicines to treat large market diseases in ophthalmology, pulmonology and cardiology. It develops genetic medicines using its proprietary invention platform, Therapeutic Vector Evolution. The company combines the power of the Nobel Prize-winning technology, directed evolution, with approximately one billion synthetic AAV capsid-derived sequences. Its product design, development and manufacturing engine creates a valuable and diverse product pipeline. The company is currently advancing five clinical-stage and two preclinical product candidates, each tailored to address rare and large market diseases. 4DMT was founded by David H. Kirn, Melissa Kotterman, Theresa Janke, and David Schaffer on September 12, 2013 and is headquartered in Emeryville, CA.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.
